OTC:ZOMDF
Zomedica Corp.
Zomedica Corp. is an OTC-traded healthcare innovator driving revenue growth through high-volume R&D spending and strategic asset expansion despite current net losses.
Key Metrics
Investment Thesis
Bull Case
ZOMDF offers exposure to high-growth medical technology at an OTC premium with revenue growing 44% over the last two years; the company's massive intangible asset base suggests valuable IP that may be undervalued by public markets; and deferred revenue growth indicates strong recurring demand for its specialized products.
Bear Case
The widening net loss from -$17M to -$47M demonstrates accelerating burn rates that threaten liquidity given limited cash reserves; operating expenses outpace gross profits significantly, indicating poor cost control or premature scaling; and the lack of positive operating cash flow makes the stock highly speculative without imminent profitability.
About Zomedica Corp.
Zomedica Corp. (ZOMDF) is a specialized healthcare technology firm operating primarily in the OTC markets, focusing on advanced medical device solutions and pharmaceutical research. The company leverages significant R&D investments to develop proprietary products for emerging therapeutic areas while managing a diverse portfolio of intangible assets. Despite recent revenue growth, the firm faces substantial operational losses as it scales its manufacturing and marketing efforts across global markets.
Analysis
Management Discussion
While revenue expanded to $27.3M in 2024, the company recorded a net loss of $47.0M driven by elevated general and administrative expenses of $29.7M and marketing spend of $17.2M. The firm utilized $17.9M in investing cash flows likely for asset acquisitions to fuel growth, yet operations consumed $23.6M in cash, resulting in a net cash decline of $5.8M despite ending balances.
Industry Overview
The medical device and pharmaceutical sector is experiencing rapid innovation driven by aging demographics and technological advancements, yet it remains capital intensive with high R&D requirements. Companies in this space often operate at a loss during growth phases but face strict regulatory hurdles and long development cycles before reaching profitability. Market consolidation is increasing as smaller players struggle to compete with established giants possessing superior balance sheets.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $18.9M | $25.2M | $27.3M |
| Cost of Revenue | $5.3M | $7.9M | $8.2M |
| Gross Profit | $13.7M | $17.3M | $19.1M |
| Operating Expenses | $35.6M | $48.9M | $70.1M |
| Operating Income | $-21.9M | $-31.6M | $-51.1M |
| R&D | $2.6M | $5.7M | $7.3M |
| G&A | $33.0M | $29.0M | $29.7M |
| Marketing | — | $14.1M | $17.2M |
| Stock-Based Comp | $7.9M | $6.3M | $2.8M |
| Depreciation | $426.0K | $830.0K | $1.5M |
| Amortization | $3.6M | $5.5M | $6.4M |
| Other OpEx | $0 | $0 | $16.0M |
| Non-Operating Income | $2.5M | $-4.3M | $3.5M |
| Interest Expense | $1.0K | $175.0K | — |
| Pre-Tax Income | $-19.4M | $-35.9M | $-47.5M |
| Income Tax | $-2.4M | $-1.3M | $-557.0K |
| Continuing Ops | $-17.0M | $-34.5M | $-47.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-17.0M | $-34.5M | $-47.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-17.0M | $-34.5M | $-47.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $123.5M | $99.9M | $81.8M |
| Cash & Equivalents | $27.4M | $13.0M | $7.0M |
| Accounts Receivable | $596.0K | $1.2M | $2.4M |
| Inventory | $2.7M | $5.1M | $5.1M |
| Prepaid Expenses | $3.8M | $2.1M | $2.3M |
| Other Current Assets | $89.0M | $78.5M | $65.0M |
| Long-Term Assets | $156.1M | $153.3M | $125.6M |
| PP&E (Net) | $6.8M | $10.3M | $24.6M |
| Intangibles | $41.8M | $55.4M | $52.5M |
| Goodwill | $64.0M | $61.6M | $45.6M |
| Operating Leases | $1.7M | $2.5M | $1.6M |
| Other LT Assets | $41.9M | $23.6M | $1.3M |
| Total Assets | $279.6M | $253.2M | $207.4M |
| Current Liabilities | $7.8M | $9.0M | $9.3M |
| Accounts Payable | — | — | $1.9M |
| Current Leases | $641.0K | $916.0K | $523.0K |
| Deferred Revenue | $207.0K | $276.0K | $331.0K |
| Taxes Payable | — | $65.0K | $117.0K |
| Other Current Liab | $7.0M | $7.8M | $0 |
| Long-Term Liabilities | $4.4M | $4.1M | $2.4M |
| LT Operating Leases | $1.1M | $1.8M | $1.3M |
| Other LT Liab | $3.1M | $2.1M | $855.0K |
| Total Liabilities | $12.2M | $13.2M | $11.7M |
| Shareholders' Equity | $267.4M | $240.0M | $195.7M |
| Retained Earnings | $-136.4M | $-170.9M | $-217.9M |
| AOCI | $-843.0K | $48.0K | $88.0K |
| Total L&E | $279.6M | $253.2M | $207.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-17.0M | $-34.5M | $-47.0M |
| Non-Cash Adjustments | $-1.1M | $20.5M | $22.4M |
| Working Capital Changes | $6.5M | $-2.0M | $943.0K |
| Cash from Operations | $-11.7M | $-16.0M | $-23.6M |
| Capital Expenditures | $787.0K | $496.0K | $5.2M |
| Cash from Investing | $-155.9M | $1.6M | $17.9M |
| Cash from Financing | $8.0K | $49.0K | $-70.0K |
| FX Effect | $-11.0K | $-49.0K | $-85.0K |
| Net Change in Cash | $-167.5M | $-14.4M | $-5.8M |
| Beginning Cash | $195.0M | $27.4M | $13.0M |
| Ending Cash | $27.4M | $13.0M | $7.0M |
Frequently Asked Questions
How does Zomedica Corp. make money?
Primary revenue streams include sales of proprietary medical devices, licensing agreements for pharmaceutical research compounds, and commercial partnerships with international distributors managing significant deferred revenue balances.
What are the main risks for ZOMDF?
Persistent net losses exceeding $47 million indicate unsustainable burn rates without clear path to profitability; heavy reliance on deferred revenue ($550M total) creates concentration risk if client contracts lapse; significant goodwill of $45.6M poses impairment risks if market conditions deteriorate; and negative operating cash flow of nearly $24 million raises concerns about liquidity sustainability.
What is ZOMDF's competitive advantage?
The company holds a substantial portfolio of operating intangible assets totaling over $52 million, providing long-term IP protection; it maintains robust cash flow from investing activities through strategic asset acquisitions; and its high gross profit margin relative to operating expenses suggests strong pricing power in niche markets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.